Administer orally, preferably 15-30 minutes before meals. Use the provided calibrated dropper for accurate measurement of the prescribed dose.

Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ). By blocking these receptors, it promotes gastric emptying and intestinal peristalsis, thereby reducing nausea and vomiting.

• •Hypersensitivity to Domperidone or any excipients
• •Prolactin-releasing pituitary tumor (prolactinoma)
• •Moderate to severe hepatic impairment
• •Conditions where stimulation of gastrointestinal motility might be harmful (e.g., gastrointestinal hemorrhage, mechanical obstruction, perforation)
• •Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin)
• •Patients with known existing prolongation of cardiac QTc intervals, significant electrolyte disturbances, or underlying cardiac diseases

Store below 30°C, in a dry place, away from direct sunlight and moisture. Keep tightly closed and out of the reach of children. Do not freeze.

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions (especially in children), and QT prolongation. Treatment is symptomatic and supportive. Gastric lavage and activated charcoal may be considered if recent ingestion. ECG monitoring is recommended.

Pregnancy Category C. Use in pregnant women only if clearly needed and the potential benefit outweighs the potential risk to the fetus. Domperidone is excreted in breast milk in small amounts; caution should be exercised and a doctor consulted before use during lactation.